2,681 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Postrock Partners LLC

Postrock Partners LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, Holdings Channel reports. The fund bought 2,681 shares of the biopharmaceutical company’s stock, valued at approximately $248,000.

A number of other large investors have also added to or reduced their stakes in GILD. Swedbank AB lifted its position in Gilead Sciences by 10.2% during the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after purchasing an additional 189,622 shares during the period. Venturi Wealth Management LLC grew its holdings in Gilead Sciences by 60.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 1,493 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 565 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its stake in Gilead Sciences by 49.9% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 8,447 shares of the biopharmaceutical company’s stock worth $708,000 after purchasing an additional 2,813 shares in the last quarter. Aptus Capital Advisors LLC boosted its stake in Gilead Sciences by 3.9% during the third quarter. Aptus Capital Advisors LLC now owns 8,263 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 309 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. grew its holdings in shares of Gilead Sciences by 0.5% in the third quarter. Oppenheimer Asset Management Inc. now owns 184,172 shares of the biopharmaceutical company’s stock valued at $15,441,000 after purchasing an additional 948 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 311,285 shares of company stock worth $31,284,910. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 0.6 %

Gilead Sciences stock opened at $113.35 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The firm’s 50 day moving average price is $101.42 and its two-hundred day moving average price is $92.47. The firm has a market cap of $141.16 billion, a PE ratio of 306.35, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.79%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on GILD shares. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Piper Sandler raised their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. UBS Group lifted their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. BMO Capital Markets upped their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Finally, Citigroup assumed coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price for the company. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.